|
Age, years, mean (SD)
|
42.3 (14.4)
|
52.0 (NA)
|
47.3 (11.6)
|
48.8 (9.8)
|
49.8 (9.3)
|
46.0 (8.6)
|
47.3 (9.7)
|
|
Female, n (%)
|
2 (50.0)
|
0 (0.0)
|
3 (75.0)
|
3 (50.0)
|
5 (83.3)
|
6 (85.7)
|
19 (67.9)
|
|
White, n (%)
|
4 (100.0)
|
1 (100.0)
|
2 (50.0)
|
6 (100.0)
|
5 (83.3)
|
6 (85.7)
|
24 (85.7)
|
|
Weight, kg, mean (SD)
|
84.7 (7.9)
|
114.2 (NA)
|
75.3 (4.4)
|
68.2 (18.7)
|
73.4 (14.6)
|
71.7 (20.5)
|
75.2 (17.1)
|
|
Diffuse cutaneous SSc, n (%)
|
3 (75.0)
|
1 (100.0)
|
3 (75.0)
|
5 (83.3)
|
6 (100.0)
|
6 (85.7)
|
24 (85.7)
|
|
Disease duration, years, mean (SD)
|
5.6 (6.2)
|
5.3 (NA)
|
5.7 (3.35)
|
6.7 (4.7)
|
3.7 (3.0)
|
5.4 (5.1)
|
5.4 (4.3)
|
|
Positive antinuclear antibody, n (%)
|
2 (50.0)
|
0 (0.0)
|
4 (100.0)
|
4 (66.7)
|
4 (66.7)
|
7 (100.0)
|
21 (75.0)
|
|
Positive anti-Scl70 antibody, n (%)
|
3 (75.0)
|
0 (0.0)
|
1 (25.0)
|
2 (33.3)
|
4 (66.7)
|
2 (28.6)
|
12 (42.9)
|
|
Elevated acute phase reactants (ESR, CRP), n (%)
|
2 (50.0)
|
1 (100.0)
|
1 (25.0)
|
4 (66.7)
|
3 (50.0)
|
3 (42.9)
|
14 (50.0)
|
|
MRSS, mean (SD)
|
22.8 (7.5)
|
31.0 (NA)
|
23.5 (7.6)
|
20.0 (9.8)
|
23.3 (12.8)
|
24.0 (5.1)
|
23.0 (8.5)
|
|
FVC, % predicted, mean (SD)
|
87.9 (10.9)
|
83.0 (NA)
|
87.0 (10.9)
|
75.0 (19.0)
|
83.8 (21.9)
|
82.1 (22.8)
|
82.5 (17.8)
|
|
DLco, % predicted, mean (SD)
|
69.8 (30.2)
|
98.0 (NA)
|
79.5 (20.9)
|
54.5 (10.0)
|
74.8 (29.2)
|
77.9 (20.7)
|
72.0 (23.1)
|
|
CD19 B cell count, cells/uL, mean (SD)
|
223.8 (209.5)
|
182.0 (NA)
|
187.3 (149.9)
|
119.2 (115.7)
|
175.8 (116.1)
|
175.3 (211.8)
|
172.3 (152.9)
|
|
CD20 B cell count, cells/uL, mean (SD)
|
221.0 (210.7)
|
174.0 (NA)
|
180.0 (135.3)
|
115.8 (113.9)
|
177.0 (116.5)
|
173.3 (211.4)
|
169.6 (151.3)
|
